Fibrolase is a snake venom metalloproteinase (SVMP) from Agkistrodon contortrix contortrix (southern copperhead) venom that exhibits direct fibrinolytic activity. This protein has been extensively studied for its potential as a therapeutic fibrinolytic agent and was developed into a recombinant analog called alfimeprase for clinical applications.
Fibrolase is a zinc metalloproteinase that belongs to the venom metalloproteinase (M12B) family, P-I subfamily PMID:1304358. The enzyme requires zinc for its catalytic activity and structural integrity PMID:1898066.
Unlike many other fibrinolytic agents, fibrolase exhibits direct fibrinolytic activity and does not require activation of plasminogen PMID:1898066. This direct action makes it particularly attractive as a therapeutic agent because it bypasses the complex plasminogen activation cascade.
Fibrolase demonstrates specific cleavage preferences characteristic of snake venom metalloproteinases. The enzyme shows preferential cleavage at X-Leu bonds PMID:1898066. Specific cleavage sites include 14-Ala-|-Leu-15 in insulin B chain and 413-Lys-|-Leu-414 in the alpha-chain of fibrinogen.
A remarkable feature of fibrolase is its lack of hemorrhagic activity, which distinguishes it from many other snake venom metalloproteinases PMID:1898066. This property makes it more suitable for therapeutic applications as it reduces the risk of bleeding complications.
Fibrolase shows no activity against a series of chromogenic p-nitroanilide substrates, indicating its selective substrate specificity PMID:1898066.
Alfimeprase is a recombinant analog of fibrolase that was developed for clinical use PMID:11369866. This recombinant version maintains the fibrinolytic properties of the native enzyme while being produced in a controlled manufacturing environment.
Alfimeprase was investigated as a treatment for various thrombotic conditions PMID:18632486. The agent received orphan drug designation from both the FDA and the European Medicines Agency for evaluation in acute peripheral arterial occlusions PMID:18632486.
One of the primary clinical applications studied was the treatment of central venous catheter (CVC) occlusions, which are common in cancer patients receiving chemotherapy PMID:18632486. Alfimeprase showed promise in dissolving these occlusive clots.
Despite initial promise, alfimeprase ultimately failed phase III clinical trials for the treatment of arterial occlusive disease and acute ischemic stroke. This represents a significant setback in the translation of this snake venom-derived therapeutic from bench to bedside.
The primary physiological substrate for fibrolase is fibrin/fibrinogen, where it cleaves specific peptide bonds to dissolve blood clots PMID:1898066. The enzyme can act on both purified fibrinogen and whole blood clots, demonstrating its effectiveness in complex biological environments.
Detailed analysis using insulin B chain as a model substrate revealed the enzyme's preference for leucine at the P1' position (the amino acid immediately C-terminal to the cleavage site) PMID:1898066.
Fibrolase is composed of 203 amino acid residues in a single polypeptide chain with a calculated molecular weight of 22,891 Da PMID:1304358. The N-terminus is blocked by a cyclized glutamine (pyroglutamic acid) residue PMID:1304358.
The protein contains six cysteine residues that form three disulfide bonds critical for structural stability PMID:1304358. The disulfide connectivity was definitively established for the recombinant analog alfimeprase as Cys-116/196, Cys-156/180, and Cys-158/163 PMID:11369866.
Structural analysis reveals that fibrolase has very low alpha-helical content (4%) but significant beta-structure (39.5%) PMID:1304358. This structural composition is consistent with its classification as a metalloproteinase.
The protein contains little or no carbohydrate and lacks asparagine-linked glycosylation sites PMID:1898066. Analysis revealed the absence of consensus N-glycosylation sequences (asparagine-X-serine/threonine) PMID:1304358.
Natural fibrolase exhibits microheterogeneity at both the N-terminus and at positions 189 and 192 PMID:1304358, suggesting natural variations in the venom extract.
As a zinc metalloproteinase, fibrolase is sensitive to metal chelators. The enzyme is inhibited by EDTA, o-phenanthroline, and tetraethylenepentamine (a specific zinc chelator) PMID:1898066. This sensitivity to metal chelators is consistent with zinc being essential for both catalytic activity and structural integrity.
Fibrolase is not inhibited by classical serine protease inhibitors including diisopropylfluorophosphate (DFP), soybean trypsin inhibitor, and Trasylol PMID:1898066. This resistance profile confirms its classification as a metalloproteinase rather than a serine protease.
The enzyme is not inhibited by p-chloromercuribenzoate, indicating that free thiol groups are not essential for its activity PMID:1898066, suggesting that the disulfide bonds provide sufficient structural stability.
The absolute requirement for zinc is demonstrated by the complete loss of activity upon zinc removal and the restoration of activity upon zinc repletion. Metal analysis confirmed that fibrolase contains exactly 1 mol of zinc per mol of protein PMID:1898066.
Fibrolase represents a unique approach to thrombolytic therapy due to several key advantages:
Direct Action: Unlike plasminogen activators such as tissue plasminogen activator (tPA), fibrolase acts directly on fibrin without requiring the plasminogen activation cascade PMID:1898066.
Non-hemorrhagic Profile: The lack of hemorrhagic activity reduces the risk of bleeding complications that are common with other thrombolytic agents PMID:1898066.
Specific Substrate Recognition: The enzyme shows selectivity for fibrin substrates over other proteins, potentially reducing off-target effects.
Despite its promising properties, the clinical development of alfimeprase faced significant challenges. The failure of phase III clinical trials highlights the complexity of translating promising preclinical results into successful clinical outcomes. Factors that may have contributed to clinical failure include:
Immunogenicity: As a foreign protein, alfimeprase may have triggered immune responses that limited its efficacy or safety.
Pharmacokinetics: The in vivo behavior of the recombinant protein may have differed from expectations based on in vitro studies.
Clinical Trial Design: The specific patient populations, dosing regimens, or outcome measures may not have been optimally designed to demonstrate efficacy.
The development of alfimeprase occurred during a period when the thrombolytic therapy field was seeking alternatives to urokinase, which had been withdrawn from the market due to manufacturing issues PMID:18632486. This created a clinical need for new fibrinolytic agents with improved safety profiles.
From a research perspective, fibrolase has provided important insights into:
Structure-Function Relationships: The detailed structural characterization has advanced understanding of metalloproteinase catalysis and specificity.
Venom Biology: Fibrolase represents an example of how evolution has optimized enzymes for specific biological functions.
Drug Development: The alfimeprase story illustrates both the potential and the challenges of developing venom-derived therapeutics.
Fibrolase is a fascinating example of a snake venom component that has been extensively characterized and developed for therapeutic applications. Its unique combination of direct fibrinolytic activity without hemorrhagic effects made it an attractive candidate for treating thrombotic conditions. While the clinical development of alfimeprase ultimately was unsuccessful, the extensive research on fibrolase has contributed significantly to our understanding of metalloproteinase structure and function, as well as the challenges of developing venom-derived therapeutics. The protein remains an important model system for studying fibrinolytic enzymes and continues to provide insights into the design of improved thrombolytic agents.